ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more


Latest Posts
1 to 16 of 329 Posts
1 2 3 ... 21
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong Kong IPO.
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin trading on June 18.
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to $273 million in milestones, plus royalties.
Week In Review: Nikang Raises $200 Million From US And China Investors
NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. NiKang was originally incubated by CBC Group (C-Bridge Capital) in 2017.
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.
Week In Review: GenScript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
GenScript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to GenScript's Legend Biotech CAR-T subsidiary. Before the investments, Legend was worth $4 billion.
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine has started to see a rolling review in Europe.
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million upfront payment for the two candidates.
Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs
Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. It currently has a portfolio of 21 products. Zai has a market cap of $14 billion and over $1 billion in cash, not including this latest raise.
Week In Review: Sinopharm Transfers $4.6 Billion In Assets, Including Two COVID-19 Vaccines
Sinopharm Group will transfer six of its vaccine companies to Beijing Tiantan Biological Products. Two of the transferring companies have approved COVID-19 vaccines, and Sinopharma said a public listing will facilitate additional sources of funding.
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in China. 
Week In Review: Three China In-Licensing Deals Add Up To $662 Million
Simcere Pharma of Nanjing announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Qihan Biotechnology raised $67 million in a Series A++ round to advance its portfolio of cell therapies.
Week In Review: China Life Science Books $1 Billion In Ten Announced Deals
Sino Biopharm announced a deal worth up to $200 million to acquire a 60% stake in Softhale, a Belgium company. Brii Biosciences, a Shanghai-US company developing anti-infectives and CNS products for China, completed a $155 million Series C financing.
Week In Review: $1.2 Billion In China Life Science Deals, IPOs, And Financings
Just two months into 2021 and it already looks as though the momentum from 2020's record-setting levels of China life science activity continues into the new year. Most 2020 metrics for China life science doubled their 2019 results.
Week In Review: Haohai Bio Enters $527 Million Deal For Dermatology Products
Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China. Haohai will pay $8 million upfront and make a $32 million investment in Eirion Series A Preferred Stock.
Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund
OrbiMed Advisors announced it has secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV. Connect Biopharma of Taicang has filed for a NASDAQ IPO that could raise $100 million.
1 to 16 of 329 Posts
1 2 3 ... 21